Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine vs Prednisone for Acute CPPD Arthritis
NCT03128905Phase 3Completed
- Sponsor
- Université Catholique de Lille
- Start
- Feb 2018
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone in calcium pyrophosphate deposition disease (CPPD) (2 arms), sponsored by Université Catholique de Lille. Primary endpoint: Change from baseline in the pain VAS at 24 hours. Started Feb 2018; status: completed.
02
Drugs
prednisone
03
Conditions
calcium pyrophosphate deposition disease (CPPD)
Beyond the preview
Go deeper on NCT03128905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128905.